Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01966367 · ClinicalTrials.gov registry record · Phase 1
CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation
A Phase 1 study of Severe Aplastic Anemia and Diamond-Blackfan Anemia, sponsored by Diane George.
- Active
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
- 1
- Study location
NCT01966367: Active Phase 1 study of Severe Aplastic Anemia and Diamond-Blackfan Anemia, sponsored by Diane George.
NCT01966367 is a Phase 1 study of Severe Aplastic Anemia and Diamond-Blackfan Anemia that is active but no longer recruiting, run by Diane George. The registered enrollment target is 37 participants, below the 124-participant average among 16 other Severe Aplastic Anemia trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01966367, a Phase 1 study of Severe Aplastic Anemia and Diamond-Blackfan Anemia, is active but no longer recruiting, sponsored by Diane George.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
- 1
- Study location
Study Summary
This study's goal is to determine the frequency and severity of acute graft versus host disease, to evaluate incidence of primary and secondary graft rejection, to assess event free survival and overall survival, to determine the time to neutrophil and platelet engraftment, to determine the time to immune reconstitution (including normalization of T, B and natural killer (NK) cell repertoire and Immunoglobulin G production), and to establish the incidence of infectious complications including bacterial, viral, fungal and atypical mycobacterial and other infections following CD34+ selection in children, adolescents and young adults receiving an allogeneic peripheral blood stem cell transplant from a family member or unrelated adult donor for a non-malignant disease.
Primary Outcome
Determine the incidence and severity of acute GVHD.
Conditions Studied
Interventions
- BIOLOGICAL CD34 Stem Cell Selection Therapy
Study Locations (1)
New York
- Morgan Stanley Children's Hospital, New York-Presbyterian, Columbia University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2013-03 |
| Est. Completion | 2030-02 |
| Phase | Phase 1 |
What the registry record for NCT01966367 still lists
NCT01966367 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 124-participant average among 16 other Severe Aplastic Anemia trials with a reported enrollment target (70% lower).
The record links to 10 conditions, with Severe Aplastic Anemia appearing as the primary indexed condition, and to 1 intervention - of which CD34 Stem Cell Selection Therapy is the first listed.
NCT01966367 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01966367 about?
NCT01966367 is a clinical study titled "CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation". This study's goal is to determine the frequency and severity of acute graft versus host disease, to evaluate incidence of primary and secondary graft rejection, to assess event free survival and overall survival, to determine the time to neutrophil and platelet engraftment, to determine the time to ...
What is the current status of trial NCT01966367?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2013-03. Estimated completion is 2030-02.
What conditions does trial NCT01966367 study?
This clinical trial studies the following conditions: Severe Aplastic Anemia, Diamond-Blackfan Anemia, Bone Marrow Failure Syndrome, Severe Congenital Neutropenia, Amegakaryocytic Thrombocytopenia.
What interventions are being tested in trial NCT01966367?
The interventions under investigation include: CD34 Stem Cell Selection Therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT01966367?
This trial is sponsored by Diane George, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01966367 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Severe Aplastic Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01966367's enrollment target sits among peer trials
37 11th of 16 higher than 5 of 16 other Severe Aplastic Anemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Severe Aplastic Anemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
RECRUITING · Phase 1
-
JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure
RECRUITING · Phase 1
-
Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia
ACTIVE NOT RECRUITING · Phase 1
-
Natural History of Acquired and Inherited Bone Marrow Failure Syndromes
RECRUITING
-
Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)
RECRUITING · Phase 2
-
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
- NCT03935984 · 37 participants · Phase 4
Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia